Antiretroviral treatment guide for adult people living with VIH/SIDA;Guía para el tratamiento antirretroviral de las personas adultas que viven con VIH/SIDA

Revista de Investigacion Clinica

Volumn 56, Issue 2, 2004, Pages 253-271

  Soto Ramírez, Luis E ^a,e   Pérez Saleme, Leticia ^b,e   Hernandez Tepichin, Griselda ^b,e   Sierra Madero, Juan ^a,e   León Juárez, Eddie Antonio ^b,e   Romo García, Javier ^b,e   Rangel Frausto, Sigfrido ^b,e   Gaona Flores, Verónica ^b,e   Jáuregui Chiu, Mario ^c,e   López Martínez, Carlos ^d,e   Vázquez Valls, Eduardo ^b,e   Varela Trejo, Carmen ^b,e  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^c Instituto de Seguridad   (Mexico)

^d Clínica Especializada Condesa Iztapalapa   (Mexico)

^e Grupo de Tratamiento en Adultos   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; CD4 ANTIGEN; CLARITHROMYCIN; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; INDINAVIR; KETOCONAZOLE; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PHENOBARBITAL; PROTEINASE INHIBITOR; RIFABUTIN; RIFAMPICIN; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ADULT; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; DEHYDRATION; DEPRESSION; DIARRHEA; DOSE RESPONSE; DRUG ERUPTION; DRUG POTENTIATION; DYSPEPSIA; GASTROINTESTINAL SYMPTOM; HEALTH CARE SYSTEM; HEALTH PROGRAM; HEMATOLOGIC DISEASE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERSENSITIVITY REACTION; INFECTION CONTROL; INSOMNIA; LIPODYSTROPHY; LIVER TOXICITY; MANIA; MEGALOCYTOSIS; METABOLIC DISORDER; MEXICO; MITOCHONDRIAL TOXICITY; MOUTH ULCER; MUSCLE DISEASE; MYOPATHY; NAUSEA; NEPHROLITHIASIS; NEURITIS; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OSTEOPENIA; PANCREATITIS; PARESTHESIA; SOMNOLENCE; STOMATITIS; STONE FORMATION; VOMITING;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-RETROVIRAL AGENTS; HIV INFECTIONS; HUMANS;

EID: 4243089486     PISSN: 00348376     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-60.
2. Kempf DJ, Rode RA, Xu Y, et al. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS 1998; 12: F9-F14.
3. Rizzardi GP, de Boer RJ, Hoover S, et al. Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA. J Clin Invest 2000: 105: 777-82.
4. Carpenter CC, Cooper DA, Fischl MA, et al. Antiretroviral therapy for HIV infection in adults. JAMA 2000; 283: 381-90.
5. Chaisson RE, Keruly JC, Moore RD. Association of initial CD4 cell count and viral load with response to highly active antiretroviral therapy. JAMA 2000; 284: 3128-9.
6. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001: 286: 2568-77.
7. Phillips AN, Staszewski S, Weber R, et al. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA 2001; 286: 2560-7.
8. US Public Health Service. Guidelines for the use of antiretroviral agents in HIV-Infected adults and adolescents. Updated November 10, 2003. Disponible en: http://www.aidsinfo.nih.gov/guidelines/
9. Flexner C. Dual protease inhibitor therapy in HIV-infected patients. Annu Rev Pharmacol Toxicol 2000; 40: 649-74.
10. Shafer RW, Smeaton L, Robbins GK, et al. For the AIDS clinical trials group 384 team. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349: 2304-15.
11. Mulligan K, Grunfeld C, Tai VW, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV-1 infection. J Acquir Immune Defic Syndr 2000; 23: 35-43.
12. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 1999; 341: 1865-73.
13. Staszewski S, Keiser P, Montaner J, et al. Abacavir-lamivudine-zidovudine vs. indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults. JAMA 2001; 285: 1155-63.
14. Staszewski S. Update on study 006-EFV AZT 3TC versus the current 'standard of care' IDV AZT 3TC. Int J Clin Pract Suppl 1999; 103: 10-15.
15. Cameron DW, Japour AJ, Xu Y, et al. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS. 1999; 13: 213-24.
16. Fletcher CV, Acosta EP, Cheng H, et al. Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects. AIDS 2000; 14: 2495-501.
17. Eron Jr J, Murphy RL, Peterson D, et al. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: Selection of Thymidine Analog Regimen Therapy (START II). AIDS 2000; 14: 1601-10.
18. Tebas P, Powderly WG, Claxton S, et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 2000; 14: F63-F67.
19. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet. 2000; 356: 1423-30.
20. Lonergan JT, Behling C, Pfander H, et al. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. Clin Infect Dis 2000; 31: 162-6.
21. Meyer D, Behrens G, Schneider A, et al. Serum lactate in nucleoside analogue treated HIV patients correlates with serum-lipids [abstract]. Antivir Ther 2000; 5(Suppl. 5): 54. Abstract P52.
22. Lalezari JP, Henry K, O'Hearn M, et al. For the TORO 1 Study group enfuvirtide, all HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348: 2175-85.
23. Yeni PG, Hammer SM, Carpenter CCJ, et al. Antiretroviral treatment for adult HIV infection in 2002. Updated recommendations of the international AIDS society-USA panel. JAMA 2002; 288: 222-35.
24. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings: Guidelines for a public health approach. Abril 2002.
25. Benson CA, Deeks SG, Brun SC, et al. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J Infect Dis. 2002; 185: 599-607.
26. British HIV Association. British HIV Association guidelines for the treatment of HIV-infected adults with antiretroviral therapy, 2003. Disponible en www.bhiva.org/guidelines/
27. Kemper CA, Witt MD, Keiser PH, et al. Sequencing of protease inhibitor therapy. AIDS. 2001; 15: 609-15.